CagriSema beats tirzepatide 5 mg on weight loss in REIMAGINE 5
Novo Nordisk's cagrilintide-semaglutide combination outperformed the lowest maintenance dose of Lilly's tirzepatide in a head-to-head obesity trial.
MH
By Maren Holt · Senior Reporter, GLP-1
Sep 28 03:00 ETSource: Pharmacy Times
The wire
- 01Pharmacy Times reports REIMAGINE 5 found CagriSema produced greater weight loss than tirzepatide 5 mg, the lowest maintenance dose of Lilly's incretin.
- 02A head-to-head win against tirzepatide shapes formulary and prescribing conversations as the amylin-plus-GLP-1 combination moves toward market.
- 03The comparator was 5 mg rather than tirzepatide's higher maintenance doses, a limitation to weigh before generalizing the result; full data and regulatory timing remain pending.
From the source
Read at pharmacytimes.comCagriSema Tops Tirzepatide 5 mg for Weight Loss in REIMAGINE 5
